Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 5;11(1):73-78.
doi: 10.1159/000505638. eCollection 2020 Jan-Apr.

Dexamethasone Implant Migration through an Iris Coloboma

Yoav Glidai  1   2 , Shulamit Schwartz  1   2 , Eyal Cohen  1   2
Affiliations
Case Reports

Dexamethasone Implant Migration through an Iris Coloboma

Yoav Glidai et al. Case Rep Ophthalmol. .

Abstract

Ozurdex® 0.7 mg (dexamethasone 0.7 mg implant, Allergan, Dublin, Ireland), an intravitreal biodegradable implant, is indicated for cystoid macular edema due to various causes. One of its known and uncommon complications is implant migration to the anterior chamber, causing corneal edema that, in some cases, is irreversible. Reported risk factors for device migration are open or defective lens capsule and prior history of vitrectomy. We present a case of dexamethasone implant migration through a congenital iris coloboma in a pseudophakic patient with an intact lens capsule. The patient is a 56-year-old pseudophakic man with a history of congenital iris coloboma, myopia, retinal tears, and a branch retinal vein occlusion with subsequent cystoid macular edema resistant to anti-VEGF medications but responsive to corticosteroids. He presented with sudden painless decreased vision in his left eye, 8 weeks following dexamethasone implant (Ozurdex) injection to the same eye. Upon presentation, he was diagnosed with corneal edema caused by anterior chamber migration of the implant. He was referred for immediate surgical intervention to extract the implant, with a resolution of the corneal edema within 2 weeks postoperatively. To conclude, this is the first case that reports Ozurdex implant migration through an iris coloboma in the setting of an intact posterior capsule. In addition, we describe a novel surgical approach for implant removal from the anterior chamber that is simple and efficient.

Keywords: Implant; Iris coloboma; Migration; Ozurdex; Surgical technique.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Slit-lamp biomicroscopy capturing dexamethasone implant dislocated through inferior iris coloboma to the anterior chamber with corneal edema and Descemet folds.
See this image and copyright information in PMC

References

    1. Haller JA, Bandello F, Belfort R, Jr, Blumenkranz MS, Gillies M, Heier J, et al. OZURDEX GENEVA Study Group Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010 Jun;117((6)):1134–1146.e3. - PubMed
    1. Rahimy E, Khurana RN. Anterior segment migration of dexamethasone implant: risk factors, complications, and management. Curr Opin Ophthalmol. 2017 May;28((3)):246–51. - PubMed
    1. Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, et al. Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014 Jan;121((1)):67–71. - PubMed
    1. Stepanov A, Codenotti M, Ramoni A, Prati M, Jiraskova N, Rozsival P, et al. Anterior chamber migration of dexamethasone intravitreal implant (Ozurdex®) through basal iridectomy (Ando) in a pseudophakic patient. Eur J Ophthalmol. 2016 Apr;26((3)):e52–4. - PubMed
    1. Stelton CR, Townsend J, Peterson LT, Khurana RN, Yeh S. Surgical Management of Anterior Chamber Migration of a Dexamethasone Intravitreal Implant. Ophthalmic Surg Lasers Imaging Retina. 2015 Jul-Aug;46((7)):756–9. - PubMed

Publication types